Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotype characterization of human melanoma cells resistant to dabrafenib.

Oncology reports - 1 Nov 2017

Cordaro Fabiola Gilda, De Presbiteris Anna Lisa, Camerlingo Rosa, Mozzillo Nicola, Pirozzi Giuseppe, Cavalcanti Ernesta, Manca Antonella, Palmieri Giuseppe, Cossu Antonio, Ciliberto Gennaro, Ascierto Paolo A, Travali Salvatore, Patriarca Eduardo J, Caputo Emilia

Abstract excerpt

In the present study, the phenotype of melanoma cells resistant to dabrafenib (a B-RAF inhibitor) was investigated, to shed more light on melanoma resistance to B-RAF inhibition. Melanoma cells resistant to dabrafenib were generated using 3 different cell lines, A375, 397 and 624.38, all carrying B-RAFV600E, and they were characterized by cytofluorometric analysis, Ion Torrent technology, immunofluorescence and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cadherins
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to MAP Kinase Signaling System

Share to Octamer Transcription Factor-3

Share to Oximes

Share to Thy-1 Antigens

Share to Vimentin

Source

Open in PubMed Open full text

Identifiers

PMID: 29048639
DOI: 10.3892/or.2017.5963
PMCID: PMC5780027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotype characterization of human melanoma cells resistant to dabrafenib.PMID 29048639Read ↗

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy ResistanceSemantic proximity Read ↗

Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.Semantic proximity Read ↗

Analysis of BRAF inhibitor resistance in melanoma cellsSemantic proximity Read ↗

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic PlasticitySemantic proximity Read ↗

Phenotype Switching in Melanoma: Implications for Progression and TherapySemantic proximity Read ↗

PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanomaSemantic proximity Read ↗

Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor.Semantic proximity Read ↗

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells.Semantic proximity Read ↗

BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells.Semantic proximity Read ↗

Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switchingSemantic proximity Read ↗

Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.Semantic proximity Read ↗

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.